TZ 161
Alternative Names: TZ-161Latest Information Update: 21 Jan 2022
At a glance
- Originator Technophage
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Spinal cord injuries
Most Recent Events
- 21 Jan 2022 Technophage files an IND/clinical trial application (CTA) for spinal cord injuries, prior to January 2022 (Technophage pipeline, January 2022)
- 26 Mar 2021 Technophage plans to file a clinical trial application/IND application for Spinal cord injuries (Technophage pipeline, March 2021)
- 26 Mar 2021 Technophage plans a clinical trial for Spinal cord injuries (Technophage pipeline, March 2021)